| Markers (number of positive studies/total studies reported) | Capsaicin/capsaicinoids dose | Potential biological effects |
| Energy expenditure ( studies) | 3–30 mg/d | Increase in EE for 30 min [12, 22–25, 27, 36, 51, 64], [15] |
| Lipid oxidation and fat loss (15/18 studies) | 1–30 mg/d | Increase in lipid oxidation and decreased abdominal/body fat [13, 18, 22–24, 27], [15] |
| Lipolysis (1/1) | 2 mg | Tolerable dose, increased plasma FFA (2 hr and 2.5 hr), and glycerol (4 hr) concentrations [16] |
| Appetite (7/9 studies) | 2–30 mg | Decrease in appetite, decrease in energy intake, and increase in satiety [13, 20–23, 28, 36, 49] |
| Weight management markers (3/3) | 2 mg | Body indices (waist circumference, hip circumference, and WHR); appetite; lipolysis [16, 28, 49] |
|
|